It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
CD8 T cells play crucial roles in immune surveillance and defense against infections and cancer. After encountering antigenic stimulation, naïve CD8 T cells differentiate and acquire effector functions, enabling them to eliminate infected or malignant cells. Traditionally, cytotoxic T cells, characterized by their ability to produce effector cytokines and release cytotoxic granules to directly kill target cells, have been recognized as the constituents of the predominant effector T-cell subset. However, emerging evidence suggests distinct subsets of effector CD8 T cells that each exhibit unique effector functions and therapeutic potential. This review highlights recent advancements in our understanding of CD8 T-cell subsets and the contributions of these cells to various disease pathologies. Understanding the diverse roles and functions of effector CD8 T-cell subsets is crucial to discern the complex dynamics of immune responses in different disease settings. Furthermore, the development of immunotherapeutic approaches that specifically target and regulate the function of distinct CD8 T-cell subsets holds great promise for precision medicine.
Expanding family of CD8 T cell: novel avenues in immunotherapy
In contrast to earlier beliefs that CD8 T cells primarily differentiate into cytotoxic T cells, recent advances have unveiled the presence of diverse subsets within the effector CD8 T cell population. Among these subsets, Tc17 cells have been extensively studied within the context of skin inflammation and the tumor microenvironment. Tc9 cells have shown links to specific autoimmune conditions alongside notable antitumor effects. Tfc cells, recognized for their role in supporting humoral responses, have also been identified within tumor microenvironments. Furthermore, regulatory CD8 T subsets have emerged in conditions such as graft-versus-host disease and autoimmune disorders, suggesting their potential contributions to immune modulation. These recent discoveries provide profound insights into the intricate landscape of immune regulation, offering promising avenues to harness or target these novel subsets for therapeutic interventions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Seoul National University, Laboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, Seoul, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
2 Seoul National University, Laboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, Seoul, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Seoul National University, BK21 Plus Program, College of Pharmacy, Seoul, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
3 Incheon National University, Division of Life Sciences, College of Life Science and Bioengineering, Incheon, Republic of Korea (GRID:grid.412977.e) (ISNI:0000 0004 0532 7395)
4 Seoul National University, Laboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, Seoul, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Seoul National University, BK21 Plus Program, College of Pharmacy, Seoul, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Seoul National University, Wide River Institute of Immunology, Hongcheon, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)





